Evidence map›Paper›PMID 30078085›Full record

ReviewCurrent gastroenterology reports2018

Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

Martin D Rosenthal, Jayshil Patel, Kyle Staton, Robert G Martindale, Frederick A Moore, Gilbert R Upchurch

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. A novelFrontiers in immunology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Martin D RosenthalDepartment of Surgery, Division of Trauma and Acute Care Surgery, University of Florida College of Medicine, PO Box 10019, Gainesville, FL, 32610-0019, USA. martin.rosenthal@surgery.ufl.edu.
Jayshil PatelDepartment of Medicine, Division of Pulmonary Critical Care, Medical College of Wisconsin, Milwaukee, WI, USA.
Kyle StatonDepartment of Surgery, Division of Trauma and Acute Care Surgery, University of Florida College of Medicine, PO Box 10019, Gainesville, FL, 32610-0019, USA.
Robert G MartindaleDepartment of Surgery, Division Gastroenterology Surgery, Oregon Health Science University, Portland, OR, USA.
Frederick A MooreDepartment of Surgery, Division of Trauma and Acute Care Surgery, University of Florida College of Medicine, PO Box 10019, Gainesville, FL, 32610-0019, USA.
Gilbert R UpchurchDepartment of Surgery, Division of Vascular Surgery, University of Florida College of Medicine, Gainesville, FL, USA.
Florida College · USUniversity of Florida · USMedical College of Wisconsin · USOregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewFish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question. RECENT

findingsThereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.

Indexed as

Cardiovascular DiseasesFish OilsHumansInflammationInflammation MediatorsFish OilsInflammation MediatorsFish oilInflammationOmega-3 fatty acidsPersistent immunosuppression inflammation catabolic syndrome (PICS)Specialized pro-resolving mediators

Identifiers

PMID30078085
OpenAlexW2886397291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.